Racecadotril Safety in Myasthenia Gravis
There is no evidence that racecadotril (an antidiarrheal enkephalinase inhibitor) poses specific risks in myasthenia gravis, and it can likely be used safely in these patients.
Clinical Reasoning
The provided evidence extensively discusses medications that can worsen myasthenia gravis, with clear guidance from ASCO guidelines 1 and other authoritative sources 2, 3. Notably, racecadotril is not mentioned in any of these comprehensive lists of contraindicated or cautionary medications.
Medications That DO Worsen Myasthenia Gravis
The ASCO guidelines explicitly state to avoid medications that can worsen myasthenia, such as β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 1. Additional research confirms these drug classes carry documented risks 4, 5, 6, 7, 8.
Why Racecadotril Appears Safe
Mechanism of action: Racecadotril inhibits enkephalinase in the gastrointestinal tract, reducing intestinal hypersecretion. This mechanism does not interfere with:
- Acetylcholine receptors (the primary target in myasthenia gravis)
- Neuromuscular junction transmission
- Cholinesterase activity
- Calcium channels or other ion channels at the neuromuscular junction
No documented neuromuscular effects: Unlike the medications flagged in guidelines (β-blockers, calcium antagonists, fluoroquinolones, aminoglycosides, macrolides), racecadotril has no known neuromuscular blocking properties.
Absence from warning lists: Comprehensive reviews of drugs that exacerbate myasthenia 4, 5, 9, 10, 11 do not include racecadotril or enkephalinase inhibitors.
Practical Recommendation
Racecadotril can be prescribed for diarrhea in myasthenia gravis patients without specific dose adjustments or contraindications. However, as with any new medication in myasthenia patients:
- Monitor for any unexpected increase in muscle weakness after initiation
- Ensure patients are on stable myasthenia treatment (typically pyridostigmine ± immunosuppression)
- Maintain awareness that symptomatic myasthenia patients with generalized disease are more vulnerable to any drug-induced changes 4
Important Caveat
The FDA drug label evidence provided 12 discusses carvedilol (a β-blocker), not racecadotril. This appears to be a database error, as carvedilol is explicitly contraindicated in myasthenia gravis per ASCO guidelines 1. Do not confuse these medications—they are entirely different drug classes with opposite safety profiles in myasthenia gravis.